The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series
Ofatumumab (OFA) is an anti-CD20 antibody. We assessed the therapeutic potential of OFA in five pediatric anti-NMDAR encephalitis patients who showed poor responses to the first-line immunotherapy. OFA treatment showed clinical improvement including alleviation of clinical symptoms and mRS decrease accompanied by anti-NMDAR antibody turning negative in 3 patients and decline in 2 patients. And all patients achieved B cell depletion after OFA treatment. During follow-up, all patients' symptoms were stable. OFA treatment is safe and effective, easy to administer, and favorable for pediatric anti-NMDAE encephalitis patients who are refractory to the first-line immunotherapy.
Authors
- Wen‐Xiong Chen (ORCID: https://orcid.org/0000-0001-9076-2006)
- Chi Hou (ORCID: https://orcid.org/0000-0002-1505-6918)
- Yanping Ran
- Yuanyuan Gao (ORCID: https://orcid.org/0000-0002-2904-5021)
- Jie Hong
- Xiaojing Li (ORCID: https://orcid.org/0000-0002-1254-9119)
- Wenxiao Wu
- Yulin Tang
- Haixia Zhu (ORCID: https://orcid.org/0000-0001-9536-9588)
- Wenlin Wu (ORCID: https://orcid.org/0000-0002-6970-4722)
- Yinting Liao
Institutions
- Guangzhou Women and Children Medical Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e40680
- Citations
- 2
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.74